the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Clinical trial NCT04978753 · UNKNOWN
Trial details
- NCT number
- NCT04978753
- Sponsor
- Li-kun Chen
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-01
- Primary completion
- 2022-05-30
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.